U.S. Chemicals Stock News

In recent weeks, Planet Labs PBC expanded its Berlin manufacturing facility plan to double production of its next-generation Pelican satellites, supported by a US$900 million backlog, new satellite deployments, and increased investment in AI-powered analytics and in-space computing partnerships. The combination of expanded European capacity, government-backed contracts from Germany and Sweden, and AI-focused collaborations positions Planet Labs more firmly in higher-value Earth observation...

Market relief rally puts Under Armour (UAA) back in focus Under Armour (UAA) moved higher following broader market optimism, as investors reacted to potential easing of hostilities in Iran and Federal Reserve comments indicating that inflation appears contained and interest rates may remain stable. See our latest analysis for Under Armour. The latest move comes after a choppy few months, with a 30 day share price return of a 14.72% decline, contrasting with a 90 day share price return of a...

In early April 2026, Oruka Therapeutics, Inc. filed an omnibus shelf registration that would allow it to issue up to US$1 billion of common stock, preferred stock, depositary shares, and warrants over time. This broad financing framework gives Oruka Therapeutics flexible access to multiple types of capital, which could be used for future clinical, operational, or transactional initiatives. Next, we’ll examine how this flexible US$1 billion shelf registration may influence Oruka Therapeutics’...

Why the latest earnings matter for Arcos Dorados Holdings (ARCO) Arcos Dorados Holdings (ARCO) is back in focus after fourth quarter results came in below expectations, with EBITDA and net income missing forecasts and an adjusted net loss catching many investors’ attention. At the same time, the board authorized a 2026 cash dividend totaling US$0.28 per share in four equal installments, giving shareholders a clearer view of planned capital returns even as they assess the recent earnings...

Viking Therapeutics recently announced it has completed patient enrollment in VANQUISH-2, its Phase 3, 78-week trial of once-weekly subcutaneous VK2735 in about 1,000 adults with type 2 diabetes who are obese or overweight. This milestone moves Viking’s lead dual GLP-1/GIP agonist closer to pivotal data in obesity and diabetes, building directly on prior Phase 2 VENTURE results showing clinically meaningful weight loss and an encouraging safety profile. We’ll now examine how completing...

In early April 2026, Donnelley Financial Solutions President Eric J. Johnson disclosed an open‑market sale of 20,280 shares, worth about US$1,000,000, in an SEC Form 4 filing, reducing his direct holding to 87,473 shares. This was his largest open‑market sale since June 2024 and, because it was not executed under a pre‑planned trading arrangement, it may raise fresh questions among investors about insider confidence and timing. We’ll now examine how this large, non‑planned insider sale could...

Setting the scene for Hub Group after recent performance Recent share performance for Hub Group (HUBG) has been mixed, with a 3.2% gain over the past week contrasting with declines over the past month and past 3 months. This has prompted closer attention from investors. See our latest analysis for Hub Group. The recent 3.2% 7 day share price return sits against a weaker 30 day and 90 day share price performance. The 1 year total shareholder return of 10.88% points to momentum that has been...

Peabody Energy (BTU) has drawn fresh attention after cutting first quarter sales expectations for its Centurion Mine due to commissioning challenges, while still keeping full year metallurgical coal volume guidance unchanged. See our latest analysis for Peabody Energy. The Centurion update landed after a sharp single day sell off of around 10% and follows other weak sessions, contributing to a 15.0% 7 day share price decline. However, the 90 day share price return of 9.6% and very large 5...

Why the Niagen partnership matters for OneSpaWorld OneSpaWorld Holdings (OSW) is back in focus after Niagen Bioscience engaged the company to offer pharmaceutical grade Niagen IV across more than 80 Medi-Spa clinics onboard high end cruise ships. This agreement broadens OneSpaWorld's wellness menu while tying into a larger clinical network, and comes as the stock recently formed a golden cross technical pattern alongside upward revisions to earnings projections. See our latest analysis for...

In its recent quarterly update, Ladder Capital Corp reported US$50.47 million in revenue, around a 26.4% year-on-year decline and below analyst expectations, alongside a miss on tangible book value per share estimates. This combination of weaker-than-expected revenue and tangible book value highlights pressure on both Ladder Capital’s income generation and balance-sheet performance versus peers. Next, we’ll examine how this earnings and tangible book value shortfall may affect Ladder...

On March 26, 2026, Oshkosh Corporation filed a definitive proxy statement urging shareholders to vote against a proposal that would require directors failing to win majority support in uncontested elections to leave the board within nine months, ahead of its May 5, 2026 annual meeting. This governance dispute coincides with improved geopolitical sentiment around tensions involving Iran, offering a fresh angle on Oshkosh’s risk profile and board accountability. Next, we’ll examine how the...

Phibro Animal Health (PAHC) is back on investors’ radar after reporting earnings and revenue that surpassed expectations, supported by stronger vaccine sales and the integration of Zoetis’ MFA business, which is reinforcing interest in its animal health portfolio. See our latest analysis for Phibro Animal Health. The share price has reacted strongly to this run of positive updates, with a 30 day share price return of 15.9% and a 90 day share price return of 44.7%. This has contributed to a...

Q4 earnings beat on EPS puts American International Group (AIG) in focus American International Group (AIG) recently reported Q4 2025 earnings per share of US$1.96 on revenue of US$6.55b, topping EPS expectations while revenue came in below estimates and putting the stock on many investors' watchlists. See our latest analysis for American International Group. The Q4 surprise on earnings comes as AIG’s 7 day share price return of 3.39% contrasts with a 90 day share price decline of 10.62%. At...

HealthEquity, Inc. recently appointed William “Bill” Gassen, president and chief executive officer of Sanford Health, to its board of directors, adding him to the Audit and Risk Committee and the Talent, Compensation and Culture Committee effective March 26, 2026. This appointment brings deep rural health system and human capital expertise into the boardroom at a time when HealthEquity is expanding its AI-enabled, consumer-focused healthcare affordability platform. Next, we’ll examine how...

In late March 2026, Horace Mann Educators announced that Vice President, Controller and Chief Accounting Officer Maureen Temchuk began a temporary maternity leave, with Chief Financial Officer Ryan Greenier stepping in as Interim Chief Accounting Officer until her expected return in early July. This short-term leadership adjustment places the company’s financial reporting and accounting oversight directly under its CFO, potentially streamlining coordination between finance, investment, and...

Chipotle Mexican Grill (CMG) is back in focus after recent investor communications pointed to a potential business rebound in 2026, supported by new menu initiatives, evolving marketing and favorable analyst sentiment. See our latest analysis for Chipotle Mexican Grill. The recent optimism around a potential business rebound in 2026 comes after a choppy period, with a 1-day share price return of 1.62% and 7-day share price return of 7.45% alongside a 90-day share price return of 13.31% and a...

Hillman Solutions recently received reiterated positive analyst coverage following its first investor day and was honored with REDI Cincinnati’s James A. Wuenker Growth Award for its Forest Fair Mall Redevelopment Project, which consolidates multiple operations into a new multipurpose facility to enhance collaboration and efficiency. This combination of analyst confidence and recognition for an efficiency-focused redevelopment underscores how Hillman is actively reshaping its operational...

In early April 2026, research outlet The Bear Cave published a critical report alleging misleading billing practices, deceptive free trials, problematic cancellation processes, and misleading telemarketing at Yelp, arguing these issues could signal weaker customer relationships and revenue quality than the company presents. Separately, a recent SEC filing showed that Chief Product Officer Craig Saldanha sold 1,200 Yelp shares on April 1, 2026, contributing to a pattern of insider selling...

Alkami Technology (ALKT) is back on investor radar after activist hedge fund JANA Partners disclosed a 5.1% stake, describing the shares as undervalued, alongside new board appointments and fresh client momentum. See our latest analysis for Alkami Technology. Recent news around JANA Partners, new board appointments and client wins has come after a tougher spell for Alkami, with a 90 day share price return of a 30.04% decline, a year to date share price return of a 26.98% decline and a three...

Copa Holdings recently reported that analysts now expect double-digit year-over-year revenue growth for the upcoming quarter, even as earnings per share forecasts have been reduced by more than 15% ahead of its next results release. This combination of stronger sales expectations but weaker profit outlook, set against Copa’s role as a hub-focused Latin American carrier in the Russell 1000, raises fresh questions about the balance between growth and profitability in its business model. With...

Merck (MRK) is back in focus after two key milestones: strong Phase 3 data for its oral PCSK9 candidate enlicitide decanoate, and fresh EU approval expanding Keytruda’s ovarian cancer use. See our latest analysis for Merck. Merck’s share price has been firming over the past few months, with a 30 day share price return of 4.4% and a 90 day share price return of 12.5%. The 1 year total shareholder return of 53.8% reflects how investors have responded to ongoing trial updates, product approvals...

Envista Holdings recently expanded its manufacturing footprint with a new facility in Suzhou, China, and rolled out 2025 product launches including OptiBond 360, SimpliCore Composite, and CaviCide HP to better serve growing regional demand. This combination of increased local production capacity and a refreshed product portfolio highlights Envista’s emphasis on aligning innovation with geographic growth opportunities. We’ll now examine how the new Suzhou facility could influence Envista’s...

Core & Main (CNM) drew fresh attention after releasing fourth quarter and full year earnings, issuing new sales guidance, completing a share repurchase, and outlining board and leadership changes related to succession planning. See our latest analysis for Core & Main. The stock’s recent pattern has been mixed, with a 7-day share price return of 5.82% around earnings and governance news, set against a 90-day share price decline of 8.02%, while the 3-year total shareholder return of 131.59%...

Constellation Brands recently became the focus of diverging analyst views ahead of its 8 April 2026 fourth-quarter earnings release, with commentary highlighting softer organic growth, shipment pressures in key beer brands, and expectations for year-over-year declines in revenue and earnings. Investors are also watching the pending CEO transition and potentially more flexible longer-term guidance, as the company faces questions about sustaining beer strength while managing tariffs, weakening...